DSMB recommends Vaxart's COVID-19 Phase 2b trial proceed; norovirus Phase 1 in H1 2025

Vaxart, Inc.

DSMB recommends Phase 2b proceed after review of 30-day safety data from 400-participant sentinel cohort.
Trial to enroll ~10,000 participants pending FDA review and BARDA approval.
Norovirus Phase 1 trial of second-gen vs first-gen constructs to start H1 2025, topline data mid-2025.
New avian influenza vaccine candidate (clade 2.3.4.4b) in preclinical studies.
Cash runway into 2026 supported by BARDA award of up to $460.7M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.